Clinical Trial Update: Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating radiotherapy plus anlotinib for locally advanced non-small cell lung cancer intolerant to concurrent chemoradiation; recruitme…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: JIANYANG WANG | Conditions: Locally Advanced Non-Small Cell Lung Cancer, Thoracic Radiotherapy | Phase 2 | Status: RECRUITING